Archive for September, 2019

Molecular diagnostics market is growing at a significant rate due to increasing awareness for the same and rising investments in the field. Genetic testing refers to a process of analysis of human DNA in any of its form or related products such as RNA, chromosomes, DNA and others. Genetic testing is widely used for detection of diseases that are related to genotype, phenotype or mutation. Also, genetic testing is done to detect karyotype for clinical purposes. Popularity of genetic testing is increasing due to various advantages offered by this procedure such as detection of genetic abnormalities in early gestation period of about 8 to 10 weeks. In addition, it also helps to determine the sex the fetus. Genetic testing market is growing at a significant rate due to increasing awareness and discoveries in the field. Of all the tests performed for genetic testing, screening for genetic mutations with Cystic Fibrosis Trans-Membrane Conductance Regulator (CFTR) gene is most widely performed.

Get Sample Copy of this report at https://www.persistencemarketresearch.com/samples/3175?source=atm

\

North America dominates the global market for genetic testing due to increasing prevalence of diseases by genetic disorders and high technological advancement in the region. Europe, followed by Asia, is expected to show high growth rate in the next few years in genetic testing market. China and India are expected to be the fastest growing genetic testing markets in Asian region. Some of the key driving forces for genetic testing market in emerging countries are increasing R&D investment, large pool of patients and rising government funding.

Request Report Methodology at https://www.persistencemarketresearch.com/methodology/3175?source=atm

Various factors such as advancements in genetic testing technologies, increasing prevalence of genetic diseases and growing awareness are driving the global genetic testing market. In addition, government initiatives and increased R&D activities in the field have been driving the genetic testing market. However, high cost involved, lack of experienced professionals and stringent regulations in some regions is restraining the global genetic testing market.

Innovation of some new techniques for genetic testing, increased efficiency and accuracy are expected to offer good opportunities for global genetic testing market. In addition, emerging markets hold good potential for growth of genetic testing market due to rising patient pool and growing awareness in these regions. Some of the major trends that have been observed in the genetic testing market are shift of focus from clinical science to bioinformatics and growing popularity of these techniques, leading to high rate of adoption of genetic testing technology. Some of the major companies dealing in genetic testing market are Abbott Laboratories, BioRad Laboratories, Abbott Molecular Inc., AutoGenomics Inc., Celera Group, PerkinElmer Inc., Quest Diagnostics Inc., ELITech Group, Roche Diagnostics Corp., Applied Biosystems Inc., Roche Molecular Diagnostics Inc., Transgenomic Inc. and others.

Key points covered in the report Report segments the market on the basis of types, application, products, technology, etc (as applicable)

The report covers geographic segmentation North America Europe Asia RoW The report provides the market size and forecast for the different segments and geographies for the period of 2010 to 2020 The report provides company profiles of some of the leading companies operating in the market The report also provides porters five forces analysis of the market.

Request to view TOC at https://www.persistencemarketresearch.com/toc/3175?source=atm

Here is the original post:
Genetic Testing Market to Record Sturdy Growth by 2020 - Commerce Gazette

Increased of genetic diseases in the fetus and fetus, such as Downs syndrome, Edwards syndrome, and Pataus syndrome, is a driving force that has a large impact on the growth of the fetal and native genetic testing market. Increasing demand for genetic testing of the fetus and newborn to identify genetic abnormalities of 8-11 months before pregnancy and to determine the sex of the fetus is a factor for the growth of this market.

Get Sample Copy of this report: https://healthcareintelligencemarkets.com/request_sample.php?id=30008

Top Key Vendors:

Ariosa Diagnostics (Roche), Berry Genomics, BGI, Biorad, Illumina, Laboratory Corporation of America, Natera, Qiagen, Sequenom, Trivitron Healthcare and Verinata health..

By Geography: North America, United States, Canada, Mexico, Others, South America,Brazil,Argentina,Others,Europe,Germany,France,Italy,Spain,UK,Others,Middle East and Africa, Saudi Arabia, UAE, Israel, Others, Asia Pacific ,India, China, Japan ,Australia, Others

The base year considered for the study is New-born Genetic Testing and the market has been examined for the forecast period of 2026.The global New-born Genetic Testingmarket can be used an an insightful understanding for a diverse readership. This informative report provides vital information about the leading key players operating across the world. The competitive landscape has been elaborated on the basis of investment and productivity carried out by top-level companies. Successful business strategies have been roped in this viable analysis of New-born Genetic Testingmarket. This report inspects the entire demand and supply chain in the global New-born Genetic Testing market. It traces the journey of the market with an adjunct summary of several case studies. It conveys the information about distributors operating in the global demanding regions. Additionally, it evaluates dynamic aspects of the industries such as New-born Genetic Testing.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward-looking perspective on different factors driving or restraining market growth

It provides a technological growth map over time to understand the industry growth rate

It provides a seven-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

It provides distinctive graphics and exemplified SWOT analysis of major market segments

Get Up To 40% Discount:https://healthcareintelligencemarkets.com/ask_for_discount.php?id=30008

Table of Content:

Chapter 1 Industry Overview of New-born Genetic Testing MarketChapter 2 Manufacturing Cost Structure Analysis of New-born Genetic TestingChapter 3 Technical Data and Manufacturing Plants Analysis of New-born Genetic TestingChapter 4 Global New-born Genetic Testing Overall Market OverviewChapter 5 New-born Genetic Testing Regional Market AnalysisChapter 6 Major Manufacturers Analysis of New-born Genetic TestingChapter 7 Development Trend of Analysis of New-born Genetic Testing MarketChapter 8 New-born Genetic Testing Marketing Type AnalysisChapter 9 Conclusion of the Global New-born Genetic Testing Market Professional Survey Report 2019Chapter 10 Continue.

For more detailshttps://healthcareintelligencemarkets.com/enquiry_before_buying.php?id=30008

About Us:

At HealthCare Intelligence Markets

Contact Us:

Address: 90, State Office Center,

90, State Street Suite 700,

Albany, NY 12207

Email: sales@healthcareintelligencemarkets.com

Web: http://www.healthcareintelligencemarkets.com

Phone: +1 (888) 616-2766

Original post:
Innovative research of New-born Genetic Testing Market 2019 with Major Key Player are Ariosa Diagnostics (Roche), Berry Genomics, BGI, Biorad,...

A new case series raises the question of whether electronic gaming may cause ventricular arrhythmias and contribute to syncope in children with certain underlying conditions.

The authors report on four instances of syncope resulting from ventricular tachycardia (VT) or ventricular fibrillation (VF) in three children with either long QT syndrome (LQTS) or catecholaminergic polymorphic VT (CPVT) who were playing electronic war games at home. The underlying conditions were previously undiagnosed in two of the children.

"We are proposing that only a very small group of children may possibly be at risk of arrhythmia during gaming," study author Christian James Turner, MB, BS, pediatric cardiologist and electrophysiologist, the Sydney Children's Hospitals Network in Australia, told theheart.org | Medscape Cardiology.

"We know that children with conditions such as long QT syndrome or CPVT are at risk for dangerous arrhythmia during certain types of sporting or swimming activities this is well documented and well-established guidelines have been formulated," Turner noted.

"We think that there may be a similar mechanism occurring when children with these conditions become very excited during particular phases of gaming, and it appeared that the events we described occurred when the child was about to win the game," he said.

The report was published online September 19 in the Correspondence section of the New England Journal of Medicine.

All three children were male, ranging in age from 10 to 15 years.

Patient 1, age 10 years, suddenly lost conscious right after winning an electronic war game and spontaneously regained consciousness afterward.

He was subsequently diagnosed with CPVT after experiencing a cardiac arrest at school. Genetic testing revealed a variant (gene encoding ryanodine receptor 2 [RYR2]), which is "likely pathogenic" according to American College of Medical Genetics and Genomics criteria, the authors explain.

Patient 2, age 15 years, already had a history of a cardiac disorder (ie, d-transposition of the great arteries with ventricular septal defect), which was treated using the Rastelli procedure.

While sitting in bed and winning an electronic war game, he became presyncopal and was diagnosed with rapid monomorphic VT. After receiving successful cardioversion in the emergency department, he received an implantable cardioverter-defibrillator (ICD) and treatment with metoprolol. However, 2 months later, he again experienced an episode before he was about to win the same game. Cardioversion by the ICD was successful.

Patient 3, age 11 years, was "animatedly" playing an electronic war game with a friend when he began having palpitations followed by collapse, after which he regained consciousness spontaneously.

No information was available on the particular stage of play at the time of the collapse.

The patient's QT interval-corrected for heart rate was found to be 570 msec, and he was diagnosed with LQTS. Subsequently, several family members also received the same diagnosis, and two unexplained deaths were identified in the family. Genetic testing is currently underway.

"Whilst the exact mechanism for the triggering of arrhythmia is likely to be varied, given that each of these three children had different conditions, one common part of the pathway is likely related to the sympathetic nervous system and adrenergic stimulation," Turner explained.

"As cardiologists, we would like to see all children having physical activities and we know that regular physical activity is good for the child's heart and brain," he commented.

"This applies even to children with underlying heart rhythm conditions, such as long QT syndrome, and for a child with one of these conditions, it is important that the families discuss suitable sporting and physical activity with their cardiologist," he said.

Although certain types of syncope such as vasovagal syncope are common and generally benign, "any episode of syncope occurring in the middle of a sporting or physical activity could potentially be a 'red flag' and should be investigated," he emphasized.

Commenting on the study for theheart.org | Medscape Cardiology, Maully Shah, MBBS, director of cardiac electrophysiology at the Children's Hospital of Philadelphia, noted that scientific guidelines "have been formulated to modify or restrict certain levels of physical activity, including swimming, in individuals with genetic diseases such as long QT syndrome and CPVT because these triggers were well documented."

This "recent report alerts us to the possibility of another trigger excitement associated with video gaming that may also provoke dangerous arrhythmias in a small subset of patients with these conditions," said Shah, who is also a professor of pediatrics, Perelman School of Medicine, University of Pennsylvania, and was not involved with the study.

So the "take-home message for practicing clinicians is to recognize that nonphysical activity may also induce adrenalin surges that can trigger life-threatening arrhythmias in a small subset of patients with certain cardiac conditions," added Shah, who is president of the Pediatric and Congenital Electrophysiology Society (PACES).

Turner added, "When a child with a condition such as long QT syndrome or CPVT is diagnosed, very effective treatment is readily available and is able to prevent further dangerous episodes."

Turner, his coauthors, and Shah have disclosed no relevant financial relationships.

N Engl J Med. 2019;381:1180-81. Article

For more theheart.org | Medscape Cardiology news, join us on Facebook and Twitter.

Continue reading here:
Can Video Gaming Trigger Dangerous Arrhythmias? - Medscape

CHICAGO (CBS) Two boys were born through a sperm donor, both were diagnosed with autism, and their mother eventually went on to learn something shocking.

The sperm donor is now linked to even more children with autism and other disabilities.

In her first TV interview, the childrens mother spoke to CBS 2s Suzanne Le Mignot about her plea for change.

Danielle Rizzos face lights up when she talks about her two boys. She calls them my life.

Ive always wanted children, and I do everything for and with my kids, she said.

Rizzo gave birth to her first son in September of 2011 through a sperm donor, known as Donor H898. Fourteen months later, her second son was born, using the same sperm, from Idant Laboratories in New York City.

The donors medical history it was clean, Rizzo said.

About a year after her first sons birth, she saw changes in his behavior.

I started to notice him stop looking at me in my eyes; stop waving Hi, and Bye, Rizzo said.

Her son was diagnosed with autism. Then, her second son received the same diagnosis.

Determined to get therapy for her children, Rizzo searched the internet. She was shocked when she found information linking Donor H898 to at least a dozen cases around the world where children were born with autism or other disabilities.

Rizzo found at least four sperm banks were selling the donors sperm.

Now that theres this donors sperm at so many sperm banks, who knows how many children are out there? she said.

She also learned from other mothers that the donor himself did not speak until after age 3.

I learned he was diagnosed with ADHD, Rizzo said.

Rizzo spent a year calling every sperm bank.

None of them would do anything, she said.

Rizzo did more research. She found a geneticist who would listen.

This seemed like the perfect experiment to study autism in genes, Rizzo said.

She is now working to get more families who used the same donor to give DNA or saliva samples for research. Rizzo also wants to see genetic testing become mandatory at all sperm banks.

There really needs to be regulation and oversight in this industry and thats why Im coming forward, Rizzo said. This needs to change.

The Food and Drug Administration requires donor sperm to be tested for sexually-transmitted diseases. Some sperm banks also do genetic testing.

Rizzo sued Idant Laboratories and accepted a judgment. Idant went out of business.

CBS 2s Le Mignot called Idants parent company and had not heard back as of early Wednesday evening.

Those interested in the study being done for the families who received sperm from donor H898 can go to this website, DonorSiblingRegistry.com.

A friend of Rizzos has also set up a GoFundMe page to defray the costs of therapy for her boys.

Read more from the original source:
Single Sperm Donor Linked To Numerous Children With Autism, Other Disabilities - CBS Chicago

Between 2001 and 2011, Indias elderly population increased from 70 million to 104 million (Census estimates). In 2011, the population over 60 years of age comprised 8.6% of the total population. With falling population growth rates this share is only expected to increase further in the coming decades. As the population ages, the burden of geriatric diseases will start to feel heavier. Of all the geriatric diseases, India is perhaps most underprepared to tackle the burden of degenerative diseases like dementia (memory loss). This is due to a lack of awareness compounded by a dearth of specialists in geriatric diseases.

Alzheimers Disease is the most common form of dementia characterised by progressive degeneration of cognitive abilities. Its symptoms range from forgetfulness in its early stages to loss of speech and immobility in its late stages. However, Alzheimers differs from other geriatric diseases in that its early symptoms are often confused with that of old age and its onset is often missed. According to the Dementia India Report 2010 by the Alzheimers and Related Disorders Society of India (ARDSI), there were around 3.7 million Indians with dementia in 2010 with the number projected to rise to 7.6 million by 2030. A general awareness about Alzheimers Disease remains low throughout the country and even lower in rural and underdeveloped areas. There is an urgent need to increase awareness about dementia in general, and about the early symptoms of Alzheimers Disease in particular. Family members and primary care physicians are best placed to recognise these early symptoms and hence, a national awareness campaign targeted towards them is likely to have the most effect.

Even within the field of medicine, research in dementia and related diseases remain low. Most of our existing knowledge and estimates of the incidence of dementia come from small regional case studies. Similar to the burden of other non-communicable diseases, there is likely to be considerable heterogeneity across the states in the prevalence of dementia brought about by lifestyle and food habits. A thorough pan-India investigation into the current incidence and burden of dementia and Alzheimers is the need of the hour. There is also a need to provide genetic testing services for the Alzheimers gene (APOE-e4) and fund clinical trials. For a disease like Alzheimers, whose risk-factors are genetic, lifestyle, and environmental, we need to conduct clinical trials specific to India and not rely on those conducted in developed countries. Better knowledge of risk-factors is likely to influence patients and family-members to seek healthcare early and allow physicians to detect dementia early.

Alzheimers Disease imposes both economic and non-economic costs beyond that on the patient as family members still provide the bulk of the caregiving. The ARDSI 2010 report estimated the total societal costs from dementia to be 147 billion INR in 2010 with a projected threefold increase by 2030. In addition to direct cost of treatment e.g. cost of medication and physicians, the bulk of these economic costs stem from informal care through loss of wages and income through absenteeism from work or withdrawal from labour force by family members. Long-term care also imposes a psychological toll on the caregiver. In the absence of reliable formal care facilities, the burden of care is borne disproportionately by women. Thus, there exists an untapped market for reliable institutional care both short-term and long-term care for Alzheimers Disease patients. The establishment of care centres will transfer the burden from the family members to trained professionals as well as lead to job-creation. This would obviously require substantial investment up-front on training healthcare workers to recognise and cater to the needs of dementia patients. The National Program for Health Care of the Elderly under the Ministry of Health and Family Welfare aims to bridge some of the gaps in the landscape of geriatric care in India through the setting up of Regional Geriatric Care Centres. However, a focus on dementia and Alzheimers Disease is missing. Currently this gap is being filled by NGOs such as ARDSI who provide certification courses on dementia care. With an increasingly aging population, investments made in training healthcare professionals is likely to pay for itself as demand for these services is only going to increase.

If India is to stay ahead of the curve and prepare for the needs of an aging population, a clearly defined public health strategy with a significant focus on research into degenerative diseases and investment in the training of healthcare personnel is much needed.

Original post:
The persistence of memory: The burden of Alzheimers Disease in India - Brookings Institution

Breast Cancer Predictive Genetic Testing Market Insights 2018, is a professional and in-depth study on the current state of the global Breast Cancer Predictive Genetic Testing industry with a focus on the Global market. The report provides key statistics on the market status of the Breast Cancer Predictive Genetic Testing manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of 2018-2025 global Breast Cancer Predictive Genetic Testing market covering all important parameters.

Request Sample Report @ https://www.researchmoz.us/enquiry.php?type=S&repid=2236941&source=atm

The key points of the Breast Cancer Predictive Genetic Testing Market report:

The report provides a basic overview of the Breast Cancer Predictive Genetic Testing industry including its definition, applications and manufacturing technology.

The report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2018-2025 market shares for each company.

Through the statistical analysis, the report depicts the global total market of Breast Cancer Predictive Genetic Testing industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export.

The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.

The report then estimates 2018-2025 market development trends of Breast Cancer Predictive Genetic Testing industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out.

The report makes some important proposals for a new project of Breast Cancer Predictive Genetic Testing Industry before evaluating its feasibility.

Make An EnquiryAbout This Report @ https://www.researchmoz.us/enquiry.php?type=E&repid=2236941&source=atm

There are 3 key segments covered in this report: competitor segment, product type segment, end use/application segment.

For competitor segment, the report includes global key players of Breast Cancer Predictive Genetic Testing are included:

RocheThermo Fisher ScientificPerkinElmerQuest DiagnosticsMyriad GeneticsIverson GeneticsCancer GeneticsOncoCyte CorporationNeoGenomicsInvitae

Market size by ProductHigh Penetrant GenesIntermediate Penetrant GenesLow Penetrant GenesMarket size by End UserHospitalsClinicsOther

Market size by RegionNorth AmericaUnited StatesCanadaMexicoAsia-PacificChinaIndiaJapanSouth KoreaAustraliaIndonesiaSingaporeMalaysiaPhilippinesThailandVietnamEuropeGermanyFranceUKItalySpainRussiaCentral & South AmericaBrazilRest of Central & South AmericaMiddle East & AfricaGCC CountriesTurkeyEgyptSouth Africa

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2236941&licType=S&source=atm

Reasons to Purchase this Report:

* Estimates 2018-2025 Breast Cancer Predictive Genetic Testing market development trends with the recent trends and SWOT analysis

* Market dynamics scenario, along with growth opportunities of the market in the years to come

* Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects

* Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.

* Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years

* Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

View post:
Breast Cancer Predictive Genetic Testing Market 2025: Research By Top Manufacturers with Market Size,Market Growth, Competitive Regions with...

SALT LAKE CITY When 7-year-old Ian Dahl was diagnosed with cancer in 1994, his parents thought he was going to die.

They were given three options for treatment, none of them certain to work, recalls Hilary Saunders, a nurse practitioner at Intermountain Healthcares Primary Childrens Hospital oncology unit. For acute myeloid leukemia, the type of cancer Dahl had, she said, no one was sure what would happen.

At that time, the success rate for treating AML was 20% or less, and that was generous, in my opinion, Saunders said.

On Nov. 11 of that year, the young boy was given a bone marrow transplant using cells harvested from his dad, the closest available match at the time and Dahls only chance for survival.

Not a day goes by when I dont think, None of this was really supposed to happen for me. ... My life, my kids, I really appreciate all the little things a lot more, Dahl, 32, of Sandy, said Thursday during a celebration of 25 years of bone marrow transplants at Primary Childrens Hospital.

He was the hospitals 17th bone marrow transplant, and the fourth who survived.

Its the start of a new you, Saunders said about a patient who gets new bone marrow, where the blood cells are produced. The old marrow is deteriorated by the cancer and new marrow makes life possible. Its a whole new immune system so your body can fight. It gives you a new outlook on life, she said.

It gives you a chance to be healthy, Dr. Michael Boyers, medical director of the pediatric blood and marrow transplant program at Primary Childrens Hospital, said Thursday. He said bone marrow transplant is a tough treatment.

In 25 years, doctors at Primary Childrens have performed more than 700 bone marrow transplants, including for cancer patients, but also certain blood-related disorders. The patients came to the hospital from 13 states and four countries.

Doctors have done 43 of the procedures this year, Boyers said.

Ten years ago, he said, bone marrow transplants were proven to cut the death rate in half for cancer patients.

It has evolved a lot, Boyers said.

Dahl doesnt remember much about his lengthy stays in the hospital as a kid, but he will never forget the bad taste of the cyclosporine he was given to combat side effects of chemotherapy, the friendly hospital staff and all the activities he was able to do in the unit, as well as what it was like to be treated like he was special.

Ian is all around, a very special patient, Saunders said, because he was one of the first to undergo the procedure, but also because Dahls family has kept in touch with the doctors and nurses who worked to save his life.

Its been fun to see him grow up. I love seeing that Ian has children, which is another thing about him that is beyond amazing, she said, adding that cancer treatments often preclude bearing children. He has always held a special place in my heart.

Dahl inherited an allergy to cats after the transplant, as his dad was allergic but Dahl wasnt prior to the procedure. He sometimes has issues with eczema, akin to his dad. But looking at him, no one would know he survived cancer as a child, using bone marrow from a family member.

Dahls father has since joined the official Bone Marrow Registry, operated by the nonprofit National Marrow Donor Program, and has had the opportunity to donate his bone marrow multiple times. Dahl said the experience has enriched the lives of everyone in his family.

It was a huge miracle for our family, he said.

Its important that everybody register, Saunders said. Its a beautiful thing to save the life of an adult or child.

The younger the better when it comes to bone marrow donors, Boyers said, as there is less pain resulting from the procedure and a quicker recovery. However, donors of all ages are needed, as well as people from various ethnic backgrounds, specifically Hispanic, Asian or Native American, he said.

Sometimes people are on the registry for years waiting to be called, Boyers said. About one in 430 registrants end up donating to a patient, as they must meet age and health guidelines and be willing to donate to any patient in need. Donors between the ages of 18 and 44 are always needed.

At the time of Dahls procedure, the national registry was quite small. Finding a match was more difficult. His dad met five of six qualifications, whereas his mother and sister each met three of six not enough to be viable.

Siblings, Boyers said, have a one in four chance of being a good match for transplantation, so the larger the registry, the better the odds are of finding a better match. Patients who share the same ancestry are most likely to match.

Be the Match, the worlds largest and most diverse registry, has nearly 35 million registrants. Healthy bone marrow, as it has for Dahl, can be the the cure for someone facing life-threatening disease.

All it takes to register as a bone marrow donor is a cotton swab collection of DNA from the mouth. A person can donate stem cells and/or marrow. For more information, visit bethematch.org.

See the original post here:
Bone marrow patient returns to celebrate 25 years of success at Primary Children's Hospital - KSL.com

T cells in the bone marrow of patients with acute myeloid leukemia (AML) over-express PD-1 leading to anti-tumor activity,1but checkpoint inhibitors have been shown to overcome this in mouse models.2 Cytarabine is known to suppress the expression of PD-1 allowing cytotoxic T lymphocytes (CTLs) to attack AML cells more efficiently, while idarubicin causes the release of antigens which prime CTLs to further promote anti-tumor activity. The combination of both idarubicin and cytarabine has resulted in remission rates of 80%, but despite this high initial response, only 3050% of patients with AML are disease-free long-term2. Alterations of dosing and treatment schedules of this standard induction method have had a limited effect on this outcome.

Professor Farhad Ravandi, The University of Texas MD Anderson Cancer Center, Houston, TX, US, and colleagues conducted a phase II trial to assess nivolumab in combination with idarubicin and cytarabine as a frontline treatment for patients with newly diagnosed AML. They hypothesised that the addition of a further anti-PD-1 agent may improve remission duration by enhancing the anti-tumor activity of CTLs2. Professor Ravandi previously presented this data at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in 2017 in Atlanta (our interview with him can be found here).

In this single-arm phase II part of the phase I/II study (NCT02464657), 44 patients aged 1860 years (>60 years if eligible for intensive chemotherapy) with newly diagnosed AML (n=42) or high-risk myelodysplastic syndrome (n=2) who had an Eastern Cooperative Oncology Group Performance (ECOG) status of 02 were eligible for inclusion induction treatment.

Induction treatment included a 1.5g/m2, 24-hour infusion of cytarabine daily on Days 14 (three days only for patients >60 years), alongside 12mg/m2 daily on days 13 of idarubicin. Nivolumab was then given on Day 24 at a dose of 3mg/kg which was repeated every two weeks for a year in responders. Initially, a run-in phase was performed with patients with relapsed AML (n=3) who received 1mg/kg nivolumab with idarubicin and cytarabine and no toxicity was observed.

Responders were given consolidation cycles of attenuated doses of idarubicin and cytarabine (up to five) or allogeneic hematopoietic stem cell transplantation (allo-HSCT). The primary endpoint was event-free survival (EFS), with relapse-free survival (RFS) and overall survival (OS) as secondary outcomes. The trial would have stopped if the median EFS was less than seven months or if there was significant toxicity associated with nivolumab use (>10%) at one year.

Grade 12

n (%)

Grade 3

n (%)

Grade 4

n (%)

Nausea

1 (2)

1 (2)

0

Diarrhea

3 (7)

7 (16)

0

Mucositis or stomatitis

1 (2)

0

0

Muscle weakness

0

1 (2)

0

Syncope

0

1 (2)

0

Elevated transaminases

3 (5)

1 (2)

0

Elevated bilirubin

0

1 (2)

0

Febrile Neutropenia

1 (2)

13 (30)

1 (2)

Rash

1 (2)

2 (5)

0

Pneumonitis

1 (2)

0

0

Colitis

1 (2)

1 (2)

1 (2)

Pancreatitis

1 (2)

1 (2)

0

Cholecystitis

0

1 (2)

0

Small bowel obstruction

0

1 (2)

0

Thrombosis or embolism

1 (2)

0

0

Despite a small sample size, short follow-up and a lack of comparator population, the study demonstrates that the use of nivolumab alongside idarubicin and cytarabine as an intensified induction therapy in patients with AML (including those over 60 years old) is safe and feasible. Patients undergoing subsequent allo-HSCT showed promising responses and no increase in complications such as severe GvHD. Whether this combination produces similar outcomes compared to standard induction therapy with or without allo-HSCT needs to be confirmed in larger, randomized trials.

Link:
Nivolumab as an addition to frontline therapy of AML in younger patients - AML Global Portal

Stem cells are found in all human beings, from the initial stages of human growth to the end of life. All stem cells are beneficial for medical research; however, each of the different kinds of stem cells has both limitations and promise. Embryonic stem cells that can be obtained from a very initial stage in human development have the prospect to develop all of the cell types in the human body. Adult stem cells are found in definite tissues in fully developed humans. Stem cells are basic cells of all multicellular animals having the ability to differentiate into a wide range of adult cells. Totipotency and self-renewal are characteristics of stem cells. However, totipotency is seen in very early embryonic stem cells. The adult stem cells owes multipotency and difference flexibility which can be exploited for next generation therapeutic options. Recently, scientists have also recognized stem cells in the placenta and umbilical cord blood that can give rise to several types of blood cells. Research for stem cells is being undertaken with the expectation of achieving major medical inventions. Scientists are attempting to develop therapies that replace or rebuild spoiled cells with the tissues generated from stem cells and offer hope to people suffering from diabetes, cancer, spinal-cord injuries, cardiovascular disease, and many other disorders.

The stem cell therapy market is segmented on the basis of type, therapeutic applications, cell source, and geography. On the basis of type, the stem cell therapy market is categorized into allogeneic stem cell therapy and autologous stem cell therapy. Allogeneic stem cell therapy includes transferring the stem cells from a healthy person (the donor) to the patients body through high-intensity radiation or chemotherapy. Allogeneic stem cell therapy is used to treat patients who do not respond fully to treatment, who have high risk of relapse, and relapse after prior successful treatment. Autologous stem cell therapy is a type of therapy that uses the person's own stem cells. These type of cells are collected earlier and returned in future. The use of stem cells is done to replace damaged cells by high doses of chemotherapy, and to treat the person's underlying disease. On the basis of therapeutic applications, the stem cell therapy market is segmented into cardiovascular diseases, wounds and injuries, musculoskeletal disorders, gastrointestinal diseases, surgeries, neurodegenerative disorders, and others. On the basis of cell source, stem cells therapy is segmented into bone marrow-derived mesenchyme stem cells, adipose tissue-derived mesenchyme stem cells, and cord blood or embryonic stem cells

Browse more detail information about this report visit at at https://www.transparencymarketresearch.com/stem-cell-therapy-market.html

By geography, the market for stem cell therapy is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America leads the stem cell therapy market owing to rising awareness among people, early treatment adoption, and new product innovations. Europe is the second leading market for stem cell therapy due to development and expansion of more efficient and advanced technologies. The Asia Pacific stem cell therapy market is also anticipated to grow at an increasing rate owing to increasing healthcare spending, adoption of western lifestyles, and growth in research and development. Asia Pacific is the fastest growing region for stem cell therapy as several players have invested in the development of new stem cell technologies. These factors are expected to drive the growth of the stem cell therapy market globally during the forecast period.

The major player in the stem cell therapy market are Regenexx, Takara Bio Company, Genea Biocells, PromoCell GmbH, CellGenix GmbH, Cellular Engineering Technologies, BIOTIME, INC., Astellas Pharma US, Inc., AlloSource, RTI Surgical, Inc., NuVasive, Inc., JCR Pharmaceuticals Co., Ltd., Holostem Terapie Avanzate S.r.l., PHARMICELL Co., Ltd, ANTEROGEN.CO., LTD., The Future of Biotechnology, and Osiris Therapeutics, Inc. Rising demand for advanced stem cell therapies will increase the competition between players in the stem cell therapy market.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Request Brochure of this report visit at https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=28262&source=atm

The study is a source of reliable data on:Market segments and sub-segmentsMarket trends and dynamicsSupply and demandMarket sizeCurrent trends/opportunities/challengesCompetitive landscapeTechnological breakthroughsValue chain and stakeholder analysis

The regional analysis covers:North America (U.S. and Canada)Latin America (Mexico, Brazil, Peru, Chile, and others)Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)Eastern Europe (Poland and Russia)Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industrys value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:A complete backdrop analysis, which includes an assessment of the parent marketImportant changes in market dynamicsMarket segmentation up to the second or third levelHistorical, current, and projected size of the market from the standpoint of both value and volumeReporting and evaluation of recent industry developmentsMarket shares and strategies of key playersEmerging niche segments and regional marketsAn objective assessment of the trajectory of the marketRecommendations to companies for strengthening their foothold in the market

Note:Although care has been taken to maintain the highest levels of accuracy in TMRs reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Request For Discount On This Report at https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=28262&source=atm

Read more from the original source:
Stem Cell Therapy Market Foraying into Emerging Economies 2017-2025 - Techdadz

GENES are the building blocks of life but like all things, they can sometimes go wrong, resulting in a range of conditions and diseases.

Repairing or replacing these genes with good ones, however, could solve or at the very least treat the problem, and this is what the emerging science of gene therapy is all about.

It was first suggested in the early-1970s that using good DNA (genes are short sections of DNA) to replace defective DNA could treat inherited diseases, and since then scientists have been trying to work out how to do it, both for inherited conditions and many others.

The British Society for Gene and Cell Therapy (bsgct.org) says the first approved human gene therapy took place in 1990, on four-year-old Ashanti DeSilva who had ADA-SCID an inherited disease that prevents normal development of the immune system. The therapy made a huge difference, meaning the little girl no longer needed to be kept in isolation and could go to school.

When the human genome was mapped nearly 20 years ago, the notion that it could potentially unlock therapies capable of fixing genes responsible for some of the worlds most devastating diseases was an idea of the future, says gene therapy expert Professor Bobby Gaspar, speaking on behalf of Jeans for Genes Day, the annual campaign for Genetic Disorders UK (geneticdisordersuk.org).

We are at the forefront of a new era of treatment for genetic diseases using gene and cell therapies. Some of these are one-time, potentially curative investigational therapies that could provide life-changing benefits to patients and their families.

Gaspar says there are currently more than 10 cell and gene therapy products approved in the European Union, ranging from products that treat cancer to rare immune deficiencies. A number of these are approved in the UK and available on its National Health Service in specialised centres.

And with nearly 3,000 clinical gene therapy trials underway worldwide, the number of available treatments is expected to grow significantly over the next few years.

Here, Gaspar a professor of paediatrics and immunology at the UCL Great Ormond Street Institute of Child Health and chief scientific officer at Orchard Therapeutics, a gene therapy company that seeks to permanently correct rare, often-fatal diseases outlines five of the ways gene therapy can cure, stop, or slow a disease...

A variety of efforts are underway to use gene therapy to treat cancer. Some types of gene therapy aim to boost the bodys immune cells to attack cancer cells, while others are designed to attack the cancer cells directly.

One way the body protects itself from cancer is through T-cells, a main component of the immune system. But some cancers are good at avoiding these protection mechanisms, says Gaspar.

Chimeric antigen receptor, or CAR T-cell therapy, is a new form of immunotherapy that uses specially altered T-cells to more specifically target cancer cells.

Some of the patients T-cells are collected from their blood, then genetically modified to produce special CAR proteins on the surface.

When these CAR T-cells are reinfused into the patient, the new receptors help the T-cells identify and attack cancer cells specifically and kill them.

There are more than 250 genetic mutations that can lead to a type of blindness called inherited retinal diseases, or IRD. People with a defect in the RPE65 gene start losing their vision in childhood.

As the disease progresses, patients experience gradual loss of peripheral and central vision, which can eventually lead to blindness.

Gene therapy for some IRD patients became available in 2017, delivering a normal copy of the RPE65 gene directly to the retinal cells at the back of the eye using a naturally-occurring virus as a delivery vehicle.

For children with the genetic disorder spinal muscular atrophy, or SMA, a rare muscular dystrophy, motor nerve cells in the spinal cord are damaged, causing patients to lose muscle strength and the ability to walk, eat or even breathe, says Gaspar.

SMA is caused by a mutation in a gene called SMN which is critical to the function of the nerves that control muscle movement. Without this gene, those nerve cells cant properly function and eventually die, leading to debilitating and often fatal muscle weakness.

Researchers recently developed the first US-approved gene therapy to treat children less than two years of age with SMA.

The therapy is designed to target the cause of SMA by replacing the missing or nonworking gene with a new, working copy of a human SMN gene, helping motor neuron cells work properly.

Researchers believe targeted gene therapy and gene editing may have widespread application for a range of infectious diseases that arent amenable to standard clinical management, including HIV.

Although HIV isnt a hereditary disease, the virus does live and replicate in DNA, Gaspar explains.

Another early but encouraging approach uses a gene editing technology combined with a new long-acting, antiretroviral treatment to suppress HIV replication and eliminate HIV from cells and organs of infected animals.

Gene editing is an approach that precisely and efficiently modifies the DNA within a cell. In this approach, gene editing can knock out a receptor called CCR5 on immune cells used by HIV to enter and invade cells. Without CCR5, HIV may no longer invade and cause disease.

One approach being investigated for a number of rare, often-fatal diseases uses gene-modified blood stem cells with a goal of permanently correcting the underlying cause of disease.

Blood stem cells are taken from the patient, and corrected outside the body by introducing a working copy of the gene into the cells. The gene-corrected cells are then put back into the patient to potentially cure the disease.

Gene-modified blood stem cells have the capacity to self-renew and, once taken up in the bone marrow, can potentially provide a lifelong supply of corrected cells. Because of their ability to become many different types of cells in the body, this approach has the potential to provide a lasting treatment for many different severe and often life-limiting inherited disorders, many of which have no approved treatment options available, says Gaspar.

For instance, ADA-SCID, sometimes referred to as bubble baby syndrome, is a disease where babies lack almost all immune protection, leading to frequent and devastating infections. Left untreated, babies rarely live past two years of age. Standard treatment options are not always effective or can carry significant risks. In 2016, the European Medicines Agency approved Strimvelis, a blood stem cell gene therapy for the treatment of ADA-SCID. Strimvelis was the first approved ex vivo gene therapy product in Europe.

Jeans for Genes Day helped fund some of the earliest work using this type of gene therapy at Great Ormond Street Hospital in 2002, when Rhys Evans, a little boy with SCID, became one of the first children worldwide to be treated by gene therapy.

Jeans for Genes Day aims to raise money for children with life-altering genetic disorders by asking people to donate money for wearing jeans to work, school or wherever they like, on any day between September 16-20. Visit jeansforgenesday.org.

More:
Five benefits of gene therapies - Echo Live

Hypogonadism is defined as hormonal disorder in which the glands (gonads & ovaries) produce little or no hormones causing its deficiency in the body. Hypogonadism in males refers to deficiency of testosterone due to dysfunction of either of the testes. Female hypogonadism refers to deficiency of estrogen or progesterone due to reduced activity of the ovaries. Hypogonadism is classified into two types: primary hypogonadism (testicular failure) and central hypogonadism (hypothalamic-pituitary axis dysfunction). Other major causes of hypogonadism include autoimmune disorder, genetic disorder, severe infections, and liver and kidney diseases. Generally, hormone and imaging tests are used to diagnose hypogonadism.

According to the Boston University School of Medicine, around 4 million to 5 million men in the U.S. were affected with hypogonadism in 2003. The incidence of hypogonadism in men aged between 40 years and 69 years in the country is around 481,000 new cases per year. According to the European Male Aging Study, the prevalence of late onset hypogonadism in men aged between 40 and 79 was 2.1% in 2016. Studies suggest that hypogonadism in adult men is often underdiagnosed and undertreated and only 5%. According to the Urology Care Foundation, hypogonadism is a chronic condition which would require lifelong treatment. The treatment for hypogonadism depends on the cause and concern about fertility and includes treatment such as hormone replacement therapy or assisted reproduction.

Men with heart disease, HIV, COPD, or renal disease have high prevalence of hypogonadism. Factors such as rising prevalence of type 2 diabetes and obesity further increase the incidence of hypogonadism. Growth of the global hypogonadism treatment market is attributed to rise in geriatric population, increase in infertility, and improved diagnosis. However, growing concerns about the potential side effects, availability of generic drugs, and preference for other natural hormonal boosters and supplements are likely to hamper the growth of the hypogonadism treatment market. Increasing awareness, awaiting approvals for new generation drugs in pipeline, and technological advancements present significant opportunities in the hypogonadism treatment market.

The primary treatment option for hypogonadism is hormone replacement therapy. Based on product type, the market has been classified into testosterone replacement therapy, estrogen therapy, and progesterone therapy. Testosterone replacement therapy is the fastest growing segment as hypogonadism is more prevalent in men. The segment is expected to hold major share of the global market during the forecast period.

Browse more detail information about this report visit at at https://www.transparencymarketresearch.com/hypogonadism-treatment-market.html

In terms of mode of administration, the hypogonadism treatment market has been broadly classified into transdermal patch, topical gel, buccal tablets, implantable pellet, intramuscular injections, and oral tablets. Transdermal patch followed by topical gels are anticipated to be the fastest growing segments as these provide steady route of administration and are easily modifiable over a short period of time. The oral and buccal tablets segments are anticipated to experience sluggish growth during the forecast period due to high side effects and liver diseases.

Based on the distribution channel they are segmented into hospital pharmacies, retail pharmacies and others. The major market share for the hypogonadism treatment market is for the retail pharmacies segment and is anticipated to rule the market during the forecast period as continuous long term treatment is required for the hypogonadism patient.

In terms of region, the global hypogonadism treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the largest market for hypogonadism treatment, accounting for more than half of the market share due to the factors such as increased adoption of newer highly advanced products, rising awareness about hormonal disorder including various treatment options available, and advancing health care infrastructure. However, Asia Pacific is anticipated to be the fastest growing market during the forecast period due to increasing urbanization and rise in the patient population.

Key players in the global hypogonadism treatment market are Bayer AG, Abbott Laboratories, Inc., Merck Serono, Sanofi, Merck & Co., Inc., Actavis, Inc., AbbVie Inc., AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Endo International plc, Ferring Holding S.A., and Laboratoires Genevrier.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Request Brochure of this report visit at https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=30392&source=atm

The study is a source of reliable data on: Market segments and sub-segments Market trends and dynamics Supply and demand Market size Current trends/opportunities/challenges Competitive landscape Technological breakthroughs Value chain and stakeholder analysis

The regional analysis covers: North America (U.S. and Canada) Latin America (Mexico, Brazil, Peru, Chile, and others) Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg) Eastern Europe (Poland and Russia) Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand) Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industrys value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report: A complete backdrop analysis, which includes an assessment of the parent market Important changes in market dynamics Market segmentation up to the second or third level Historical, current, and projected size of the market from the standpoint of both value and volume Reporting and evaluation of recent industry developments Market shares and strategies of key players Emerging niche segments and regional markets An objective assessment of the trajectory of the market Recommendations to companies for strengthening their foothold in the market

Note:Although care has been taken to maintain the highest levels of accuracy in TMRs reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Request For Discount On This Report at https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=30392&source=atm

See the rest here:
Hypogonadism Treatment Market : Opportunities, Demand and Forecasts, 2017-2025 - Rapid News Network

Male hypogonadism is a condition in males wherein the testes depict a significantly reduced functioning level than normal. Reduction in rate of biosynthesis of the male sex hormones consequently results into male hypogonadism, which can vary in terms of severity among individuals. Partial or complete infertility are among major end-results entailing male hypogonadism, which in turn have created the need for effective treatment. XploreMR has published a new comprehensive research report titled, Male Hypogonadism Market: Global Industry Analysis (2012-2016) and Forecast (2017-2026). The report covers present market scenario as well as imparts future growth prospects of the male hypogonadism market for the period between 2017 and 2026. The report also engulfs key drivers, hindrances, opportunities and trends that are affecting expansion of the global male hypogonadism market. The report offers an overall picture of the global male hypogonadism market, in order to help businesses seeking opportunities for making investments in the market.

Get Sample Copy of this report at https://www.xploremr.com/connectus/sample/517

Structure of the Report

The report provides an exhaustive synopsis of the global male hypogonadism market, engulfing an executive summary that elucidates the core trends influencing the market expansion. This chapter also sheds light on impacts that the dynamics are likely to pose on growth of the market in the long run. The report also imparts figures appertaining to CAGRs from a historical and forecast point of view. An overview of the global male hypogonadism market follows the executive summary, and issues a clear picture of the markets scope to the report readers. The overview includes a concise market introduction succeeded by a formal definition of male hypogonadism. Chapters subsequent to the overview elaborates several dynamics including driving factors, limitations and prospects being observed in the market through the forecast period. Meanwhile these chapter also inundate detailed insights related to the bottom line of enterprises, global economy and fiscal stimulus.

Browse Full Report at https://www.xploremr.com/report/517/global-male-hypogonadism-market

Competition Landscape

This analytical research report on the global male hypogonadism market is a complete package, which includes intelligence on key participants underpinning the market expansion. In the last chapter of the report, which elucidates the competitive scenario of the market, strategies implemented by the market players, along with their product overview, company overview, key financials, key developments and SWOT analysis has been rendered exhaustively. In addition, region-wide spread of these market players, their future expansion plans, market shares, revenues, and mergers & acquisition activities between them have been described in detail in this concluding chapter of the report. An intensity map has been employed in the report to profile the market players situated across geographies.

Research Methodology

Credibility of the researched statistics and data is backed by the unique research methodology employed by the analysts at XMR, which ensures higher accuracy. XMRs research report on the global male hypogonadism market can assist its readers in gaining detailed insights on many different aspects governing the market around key regional segments included in the report. The report readers can further slate key strategies for tapping into vital revenue pockets and gaining benefits over the intensifying competition in the market. Information presented in the report has been scrutinized and monitored thoroughly by XMRs industry experts. Figures and numbers offered in the report have also been validated by the analysts in order to facilitate strategic decision making for the report readers.

Buy Full Report at https://www.xploremr.com/cart/517/SL

Read the original:
Male Hypogonadism Market To Increase at Steady Growth Rate - Fortune Enterpriser

Hypogonadism refers to diminished activity of reproductive organs producing little or no hormones. In males, hypogonadism refers to the decrease in either of the functions of the testes i.e. sperm production and testosterone production. It affects the men of all ages. While in females, hypogonadism refers to decreased activity of ovaries leading to reduction in the levels of estrogen and progesterone. Hypogonadism may lead to infertility, fatigue, muscle loss, depression, poor concentration and memory and reduced libido. Hypogonadism is classified into two categories namely, primary and secondary hypogonadism, based on the causative factors. Primary hypogonadism (hypergonadotropic hypogonadism) refers to abnormality in the gonads or testicles responsible for low androgen and estrogen levels. Whereas, in secondary hypogonadism (hypogonadotropic hypogonadism), the problem lies in the brain. The hypothalamus and pituitary gland in the brain, which control the gonads, arent working properly.

HypogonadismTreatment Market: Drivers and Restraints

Lack of sex hormones can lead to other complaints like increased risk of heart disease and osteoporosis, due to thinning of bones. This has led to the growth of hypogonadism treatment market. Moreover, the market has presence of patented brands with huge sales. Hypogonadism incidence will rise with increasing age and increasing incidence of obesity and rheumatoid arthritis. In addition, changing lifestyle habits associated with smoking and increasing stress levels also lead to reduced androgen and estrogen levels. These are some of the driving force for hypogonadism treatment market. However, the entry of generics would lead to sales erosion of the top brands in the market, thus restraining the hypogonadism treatment market to grow to certain extent.

HypogonadismTreatment Market: Segmentation

The hypogonadism treatment market can be segmented based on product type, distribution channel and geography.

Based on product type, hypogonadism treatment market can be segmented as follows:

Testosterone Replacement Therapy

Injection

Patch

Gel

Lozenge

Estrogen Therapy

Progesterone Therapy

Based on distribution channel, hypogonadism treatment market can be segmented as follows:

Hospitals including hospital pharmacies

Clinics

Get Sample Copy of this report at https://www.futuremarketinsights.com/reports/sample/rep-gb-1328?source=atm

Retail pharmacies

HypogonadismTreatment Market: Overview

The treatment modality for hypogonadism mainly incudes testosterone replacement through exogenous administration. However, for spermatogenesis, gonadotropins are preferred as testosterone is identified to be less effective. In females, estrogen and progesterone hormones are replaced by exogenous administration. Therefore, the market is analyzed based on hormonal replacement therapy as testosterone, gonadotropins, estrogen and progesterone. Pre-menopausal women can benefit from estrogen that comes in pill or patch form. Treatment for males and females is similar if the hypogonadism is due to a tumor on the pituitary gland. Treatment may include radiation, medication or surgery to shrink or remove the tumor.

HypogonadismTreatment Market: Region-wise Outlook

Region wise, the global hypogonadism treatment marketis classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America is the largest market for hypogonadism treatment with the presence of high prevalence of the disease. However, the industry will be experiencing higher demand from the developing regions such as Latin America, Asia-Pacific, Middle-East and Africa.

HypogonadismTreatment Market: Key Players

Some of the key players in the hypogonadism treatment market include Abbott Laboratories, Inc., Bayer AG, Eli Lilly and Company, Merck Serono, Merck & Co., Inc., Actavis, Inc. and Sanofi S.A.

The report covers exhaustive analysis on:

Market Segments

Market Dynamics

Market Size

Supply & Demand

Current Trends/Issues/Challenges

Competition & Companies involved

Technology

Value Chain

Regional analysis includes

Request to view TOC at https://www.futuremarketinsights.com/toc/rep-gb-1328?source=atm

North America (U.S., Canada)

Latin America (Mexico, Brazil)

Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)

Eastern Europe (Russia, Poland, Rest Of Eastern Europe)

Asia Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)

Japan

Middle East and Africa (GCC, S. Africa, N. Africa, Rest Of MEA)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

Detailed overview of parent market

Changing market dynamics in the industry

In-depth market segmentation

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape

Strategies of key players and products offered

Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance

Must-have information for market players to sustain and enhance their market footprint.

NOTE All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

Request Customization for this report at https://www.futuremarketinsights.com/customization-available/rep-gb-1328?source=atm

Read the original post:
Hypogonadism Treatment Market Size, Scope, Manufacturing Cost Analysis, and Strategies - Herald Space

The male sex hormone androgens and anabolic steroids include di-hydro-testosterone, testosterone, and other agents. Androgen and anabolic steroid stimulate the development of male sex organs and male sexual characters such as growth of beard and deepening of voice. Various types of tissues grow due to stimulation of anabolic steroids, especially muscle and bone. Rise in red blood cells production is due to anabolic effects. Androgens and anabolic steroids are used for the treatment of breast cancer in women, impotence, hypogonadism in men, and replacement therapy for delayed puberty in adolescent boys. Androgens and anabolic steroids are also used for the treatment of various conditions with hormonal imbalance, weight loss, osteoporosis, and anemia.

Hypogonadism in men is caused by deficiency of androgen that adversely affects quality of life and multiple organ functions. Impotence is when men are unable to get erection. Impotence in men is primarily caused due to tiredness, lack of sleep, anxiety, and excessive intake of alcohol. Breast cancer in women is uncontrollable growth of the cells in the breast. These cells form tumor that can be felt as a lump or can often be seen on an X-ray. If these cells invade surrounding tissues, it is termed as malignant cancer.

Increase in geriatric population drives the androgens and anabolic steroids market, as older men are more prone to hypogonadism. Additionally, rise in obesity in men propels the global androgens and anabolic steroids market. The increasing poor health status especially in the developing countries is projected to fuel the growth of the market during the forecast period. Moreover, rise in government initiatives for better health care is attributed to the growth of the global androgens and anabolic steroids market. Increase in prevalence of hypogonadism among men is anticipated to augment the global androgens and anabolic steroids market during the forecast period. Rise in impotence among men due to obesity and tiredness is expected to boost demand for androgens and anabolic steroids during the forecast period.

Browse more detail information about this report visit at at https://www.transparencymarketresearch.com/androgens-anabolic-steroids-market.html

The global androgens and anabolic steroids market can be segmented based on dosage form, disease type, end-user, and region. In terms of dosage form, the market can be categorized into oral/buccal, intranasal sprays, implantable pellets, transdermal patches and gels, and intramuscular injections. Based on disease type, the global androgens and anabolic steroids market can be divided into breast cancer in women, impotence, hypogonadism in men, and delayed puberty in adolescent boys. In terms of end-user, the market can be classified into online pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the market in 2016, owing to increased availability of drugs and hospitals being the first point of contact for treatment.

Geographically, the global androgens and anabolic steroids market can be segmented into Latin America, Asia Pacific, Europe, North America, and Middle East & Africa. North America held the largest market share in 2016, due to increased prevalence of breast cancer in women. According to many researches, breast cancer is one of the leading causes of death in the U.S. Europe held the second largest market share in 2016, due to increased prevalence of hypogonadism in men and delayed puberty in adolescent boys. The market in Asia Pacific is anticipated to grow at a rapid pace during the forecast period owing to increased government initiatives to eradicate breast cancer. The global androgens and anabolic steroids market in Middle East & Africa is expected to be driven by increased prevalence of impotence, hypogonadism in men, and delayed puberty in adolescent boys. The market in Latin America is projected to witness strong growth during the forecast period due to increased government initiatives in the health care sector.

Key players in the global androgens and anabolic steroids market include Unimed Pharmaceuticals, Inc. and Valeant Pharmaceuticals North America LLC.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Request Brochure of this report visit at https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=39500&source=atm

The study is a source of reliable data on: Market segments and sub-segments Market trends and dynamics Supply and demand Market size Current trends/opportunities/challenges Competitive landscape Technological breakthroughs Value chain and stakeholder analysis

The regional analysis covers: North America (U.S. and Canada) Latin America (Mexico, Brazil, Peru, Chile, and others) Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg) Eastern Europe (Poland and Russia) Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand) Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industrys value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report: A complete backdrop analysis, which includes an assessment of the parent market Important changes in market dynamics Market segmentation up to the second or third level Historical, current, and projected size of the market from the standpoint of both value and volume Reporting and evaluation of recent industry developments Market shares and strategies of key players Emerging niche segments and regional markets An objective assessment of the trajectory of the market Recommendations to companies for strengthening their foothold in the market

Note:Although care has been taken to maintain the highest levels of accuracy in TMRs reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Request For Discount On This Report at https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=39500&source=atm

The rest is here:
Androgens and Anabolic Steroids Market : Latest Innovations, Drivers and Industry Key Events 2018-2030 - RedfoxInfo

Latest Study on Industrial Growth of Global Hypogonadism Drug Market. A detailed study accumulated to offer Latest insights about acute features of the Hypogonadism Drug market. The report contains different market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary and SWOT analysis. Some are the key players taken under coverage for this study are AbbVie Inc., ALLERGAN, AstraZeneca, Bayer AG., Eli Lilly and Company, Clarus Therapeutics, Endo Pharmaceuticals Inc, Merck & Co., Inc., Ferring B.V., Richter Gedeon Vegyeszeti Gyar Nyrt, IBSA Institut Biochimque SA, Laboratoires Genevrier., Teva Pharmaceutical Industries Ltd, Lipocine Inc., Antares Pharma, Pfizer Inc., Aytu BioScience, Inc., Diurnal, HYUNDAIPHARM. Co Ltd., Perrigo Company plc, Bio-Techne.

Global hypogonadism drug market is rising gradually with a substantial CAGR in the forecast period of 2019-2026. Growing number hypogonadism population and robust product pipeline are the key drivers for market growth.

Click to get Global Hypogonadism Drug Market Research Sample PDF Copy Here @: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hypogonadism-drug-market

Drivers and Restraints of the Hypogonadism Drug Industry

Market Drivers

Increase in prevalence rate of hypogonadism worldwide acts as a driver for the market

Increase in the rate of research and development initiatives is driving the market

Rising awareness about hypogonadism therapy and technological advancement is driving the market growth

Ongoing clinical trials is being carried out by many pharmaceuticals companies which acts as a driver for the market

Market Restraints

Effective treatment is either unavailable or unaffordable

Patent expiry of major drugs and introduction of generic drugs of branded version is expected to restrain the growth if the market

Global Hypogonadism Drug Market Overview:

If you are involved in the Hypogonadism Drug industry or intend to be, then this study will provide you comprehensive outlook. Its vital you keep your market knowledge up to date segmented by Type, Application, Channel (Direct Sales, Distributor). If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide customization according to your requirement.

With the clear understanding of customer requirement, one method or combination of many methods have been used to construct the most excellent Hypogonadism Drug market research report. Market parameters covered in Hypogonadism Drug report can be listed as market definition, currency and pricing, market segmentation, market overview, premium insights, key insights and company profile of the key market players. The verified, best and advanced methods and tools such as SWOT analysis and Porters Five Forces Analysis are used carefully while generating this Hypogonadism Drug market research report. The Hypogonadism Drug report is highly beneficial in planning of production, product launches, costing, inventory, purchasing and marketing strategies.

View Detailed Table of Content @ https://www.databridgemarketresearch.com/toc/?dbmr=global-hypogonadism-drug-market

The titled segments and sub-section of the market are illuminated below:

By Type: Hypergonadotropic Hypogonadism and Hypogonadotropic Hypogonadism

By Therapy Type: Testosterone Replacement Therapy and Steroid Replacement Therapy

By Mechanism of Action Type: Steroidal Androgens &Gonadotropins

By Route of Administration: Oral, Injectable, Tropical

By End- Users: Hospitals, Homecare, Specialty Clinics

Region Included are: United States, Europe, China, Japan, Southeast Asia, India & Central & South America

Top Players in the Market are: AbbVie Inc., ALLERGAN, AstraZeneca, Bayer AG., Eli Lilly and Company, Clarus Therapeutics, Endo Pharmaceuticals Inc, Merck & Co., Inc., Ferring B.V., Richter Gedeon Vegyeszeti Gyar Nyrt, IBSA Institut Biochimque SA, Laboratoires Genevrier., Teva Pharmaceutical Industries Ltd, Lipocine Inc., Antares Pharma, Pfizer Inc., Aytu BioScience, Inc., Diurnal, HYUNDAIPHARM. Co Ltd., Perrigo Company plc, Bio-Techne

To stay ahead of the competition, a thorough idea about the competitive landscape, their product range, their strategies, and future prospects are very valuable. This Hypogonadism Drug market research report involves a key data and information about the market, emerging trends, product usage, motivating factors for customers and competitors, restraints, brand positioning, and customer behaviour, which is of utmost importance when it comes to achieving a success in the competitive marketplace. This market research report is all-inclusive and encompasses various parameters of market. Hypogonadism Drug market research report comprises of the major market insights that takes your business to the next level of success and growth.

Important Features that are under offering & key highlights of the report:

Detailed overview of Hypogonadism Drug market

Changing market dynamics of the industry

In-depth market segmentation by Type, Application etc.

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape of Hypogonadism Drug market

Strategies of key players and product offerings

Potential and niche segments/regions exhibiting promising growth

A neutral perspective towards Hypogonadism Drug market performance

Must-have information for market players to sustain and enhance their market footprint

Buy Full Copy Global Hypogonadism Drug Report @ https://www.databridgemarketresearch.com/checkout/buy/enterprise/global-hypogonadism-drug-market

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

Continued here:
Hypogonadism Drug Market Shows Strong Growth| Endo Pharmaceuticals, Clarus Therapeutics, Perrigo - Business Intelligence

Northland Securities set a $10.00 price target on Aytu Bioscience (NASDAQ:AYTU) in a research note released on Friday morning, TipRanks reports. The firm currently has a buy rating on the stock.

Several other analysts have also issued reports on AYTU. ValuEngine upgraded shares of Aytu Bioscience from a hold rating to a buy rating in a research report on Thursday, August 1st. Zacks Investment Research lowered shares of Aytu Bioscience from a buy rating to a hold rating in a research report on Friday, August 2nd.

NASDAQ AYTU opened at $1.43 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 4.10 and a quick ratio of 3.76. The firm has a market capitalization of $23.20 million, a price-to-earnings ratio of -0.05 and a beta of 4.65. The companys fifty day moving average is $1.41 and its two-hundred day moving average is $1.69. Aytu Bioscience has a 52-week low of $0.68 and a 52-week high of $4.80.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Searle & CO. grew its position in Aytu Bioscience by 1,241.6% in the 2nd quarter. Searle & CO. now owns 201,247 shares of the companys stock worth $380,000 after purchasing an additional 186,247 shares during the last quarter. BlackRock Inc. acquired a new stake in Aytu Bioscience in the 2nd quarter worth $36,000. Finally, Bank of New York Mellon Corp acquired a new stake in Aytu Bioscience in the 2nd quarter worth $75,000. Institutional investors own 19.20% of the companys stock.

About Aytu Bioscience

Aytu BioScience, Inc, a specialty healthcare company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and ZolpiMist, an oral spray for the treatment of insomnia.

Featured Article: Why is the LIBOR significant?

Receive News & Ratings for Aytu Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

More here:
Northland Securities Analysts Give Aytu Bioscience (NASDAQ:AYTU) a $10.00 Price Target - TechNewsObserver

Testosterone Replacement Therapy Global Market 2019-2024 covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies for this market. Global Testosterone Replacement Therapy Market report provides strategists, marketers and senior management with the critical information they need to assess the global Testosterone Replacement Therapy sector.

The market size section gives the Testosterone Replacement Therapy market revenues, covering both the historic growth of the market and forecasting the future.

AccessGlobal Testosterone Replacement Therapy Market Research ReportDetails at: athttps://www.pioneerreports.com/report/301292

About Testosterone Replacement Therapy Industry

Testosterone deficiency, also referred to as hypogonadism, is a common problem among men aged between 40 and 79 years, with some studies stating that nearly 30% of all men worldwide are affected by hypogonadism. As the incidence of testosterone deficiency increases, it is expected that the demand for TRT will also show a simultaneous increase.

The global average price of testosterone replacement therapy is in the decreasing trend, from 45.4 USD/Unit in 2012 to 34.9 USD/Unit in 2016. With the situation of global economy, prices will be in decreasing trend in the following five years.

The classification of testosterone replacement therapy includes gels, injections, patches and other types, and the proportion of gels in 2016 is about 72%.

Testosterone replacement therapy is widely sold in hospitals, clinics and other field. The most proportion of testosterone replacement therapy is sold in clinics, and the consumption proportion is about 43%.

North America region is the largest supplier of testosterone replacement therapy, with a production market share nearly 86% in 2016. Europe is the second largest supplier of Testosterone Replacement Therapy, enjoying production market share nearly 9.9% in 2016.

North America is the largest consumption place, with a consumption market share nearly 83% in 2016. Following North America, Europe is the second largest consumption place with the consumption market share of 12%.

Market competition is intense. AbbVie, Endo International, Eli Lilly, Pfizer, Actavis (Allergan)Bayer, etc. are the leaders of the industry. The top five players together held about 80% of the market in the same year and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.

The worldwide market for Testosterone Replacement Therapy is expected to grow at a CAGR of roughly -4.2% over the next five years, will reach 1410 million US$ in 2024, from 1820 million US$ in 2019, according to a new GIR (Global Info Research) study.This report focuses on the Testosterone Replacement Therapy in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

The overviews, SWOT analysis and strategies of each vendor in the Testosterone Replacement Therapy market provide understanding about the market forces and how those can be exploited to create future opportunities.

Key Players in this Testosterone Replacement Therapy market are:

Request for Sample Copy of this Testosterone Replacement Therapy Market Report athttps://www.pioneerreports.com/request-sample/301292

Production Analysis:SWOT analysis of major key players ofTestosterone Replacement Therapy industry based on a Strengths, Weaknesses, companys internal & external environments. , Opportunities and Threats. . It also includesProduction, Revenue, and average product price and market shares of key players. Those data are further drilled down with Manufacturing Base Distribution, Production Area and Product Type. Major points like Competitive Situation and Trends, Concentration Rate Mergers & Acquisitions, Expansion which are vital information to grow/establish a business is also provided.

Application of Testosterone Replacement Therapy Market are:

Product Segment Analysis of the Testosterone Replacement Therapy Market is:

Look into Table of Content of Testosterone Replacement Therapy Market Report at https://www.pioneerreports.com/TOC/301292

Regions Covered in Testosterone Replacement Therapy Market are:-

Inquire for further detailed information of Testosterone Replacement Therapy Market Report at:https://www.pioneerreports.com/pre-order/301292

Why should you buy Testosterone Replacement Therapy Market Report?

In this study, the years considered to estimate the market size ofTestosterone Replacement Therapy Market are as follows:-

Single User Licence Price: USD 3480

No Of Pages in Testosterone Replacement Therapy Market Report: 120

Purchase of Testosterone Replacement Therapy Market Report at:https://www.pioneerreports.com/checkout/301292

More:
Global Testosterone Replacement Therapy Market Economic Trends, Industry Development, Challenges, Forecast and Strategies To 2024 - Manufacturing News...

Despite critics' claims of junk science, the Republican-led Ohio Senate held its first hearing Wednesday on a bill that would require doctors who provide medication for an abortion to tell their patients that the procedure could be reversed.

The proposal, under consideration by the Health, Human Services and Medicaid Committee, is controversial because many medical expertssay the claim is false and not supported by science.

The legislative debate cameabout the same time that news broke that Toledo had become one of the largest cities in the nation without a clinic providing surgical abortions; its sole remaining facility surrendered its license for such procedures to the state on Sept. 10. Ohio Department of Health spokesman Russ Kennedy said Capital Care Network of Toledo's new owners decided to perform only chemically induced abortions.

Senate Bill 155, sponsored by Sen. Peggy Lehner, R-Kettering, would mandate that at least 24 hours before prescribing medication to terminate a pregnancy, doctors provide women with information stating that it may be possible to reverse the intended effects of a mifepristone abortion if she changes her mind, but time is of the essence.

Doctors who fail to give patients such information would face a first-degree criminal misdemeanor, which carries a penalty of up to six months in jail and a fine of $1,000. Subsequent violations would be fourth-degree felonies with the possibility of an 18-month sentence.

In testimony Wednesday, Lehner told committee members that she wants toensure that women have true choice.

This legislation is intended to give another choice to women who are in desperate situations. We are not forcing anyone to take the abortion-pill reversal treatment we simply want to give women more information on another option available to them, Lehner said.

Sen. Cecil Thomas, D-Cincinnati, said the bill would require doctors to give patients untested information.

Wouldnt it be wise to wait until the Food and Drug Administration had proved (the medication) for abortion reversal? he asked Lehner.

Lehner said it has been successfully used for years to prevent women from having miscarriages.I dont know what there is to wait for," she said.

If there is something that can help a woman who has changed her mind not live with the regret that she would have if she proceeded with the abortion, (it) is something that ought to be available to her.

Eight other states have passed similar laws. Last week, a federal judge blocked North Dakotas law, finding that assertions that abortions could be reversed were unproven and that the state should not require doctors to give patients misleading and inaccurate information. Arizona lawmakers repealed a state law earlier this year after it was challenged in court.

Both the American Medical Association, which was a plaintiff in the North Dakota lawsuit, and the American College of Obstetrics and Gynecology have disputed claims that the effects of an abortion pill can be reversed.

Jamie Miracle, deputy director of NARAL Pro-Choice Ohio, said such laws require physicians to provide patients with medically inaccurate information at best, and potentially harmful information at worse.

Medication abortions are generally an option for women in the first 10 weeks of pregnancy. Of the nearly 21,000 abortions performed in Ohio in 2017, the most recent data available from the health department, more than a quarter involved medicine; nearly all used mifepristone.

Typically, a woman is given two drugs: She first takes mifepristone to block the progesterone hormone that helps maintain pregnancy, followed some hours later by misoprostol, which makes the uterus contract and expel the embryo to complete the abortion.

Backers ofabortion reversal contend that the medication-based procedure could be reversed if a woman has not taken the second pill and she is given progesterone to counter the effects of mifepristone.

Lehner cited a 2018 study by Dr. George Delgado finding that high doses of progesterone successfully reversed abortions in 64% to 68% of cases without increased risk of birth defects. Critics have discounted the finding, saying the analysis was not scientific and did not use a control group for comparison.

Meanwhile, abortion-rights opponents celebrated developments in Toledo.

"No more babies will be torn apart within their mother's womb here in Toledo," said Ed Sitter, executive director of Greater Toledo Right to Life.

Stephanie Ranade Krider, vice president of Ohio Right to Life, said, "This clinic has acted in a reckless and above-the-law manner, putting women's health and safety at risk for years. ... While this facility will undoubtedly continue to profit off of women seeking chemical abortions, with over 1,300 abortions in Lucas County in 2017, the loss of their surgical license will save many lives."

Kellie Copeland, NARAL Pro-Choice Ohio's executive director, said, "These changes are happening as a natural part of running a health-care facility and unrelated to any politically motivated actions from the state legislature or administration."

ccandisky@dispatch.com

@ccandisky

drowland@dispatch.com

@darreldrowland

Link:
Abortion pill 'reversals' debated in Ohio as Toledo clinic halts surgeries to end pregnancies - The Columbus Dispatch

The frequent night feedings. The fussing that seemingly cant be soothed. The rearranging of your days to tend to the constant needs of a brand new baby. It can all catch up to any new parent.

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services.Policy

While we typically associate the baby blues and postpartum depression with women, new fathers can experience serious mood changes after bringing baby home, too.

In fact, paternal postnatal depression is wildly common, says psychologist Scott Bea, PsyD. About 10% of fathers become depressed before or just after their baby is born, according to research published in the Journal of the American Medical Association.

Postpartum blues are especially common three to six months after the birth, with as many as one in four dads experiencing symptoms.

The reason is partly biological, Dr. Bea says. Everyone knows that mothers hormones change a lot during and after pregnancy. But theres evidence that fathers also experience real changes in their hormone levels after a baby is born, he explains.

And plenty of non-hormonal factors are at play, too:

Symptoms of depression can look different in men and women. Some of the more common signs in men include:

Men who have a history of depression might be at greaterrisk of postpartum depression. So are new fathers whose partners also havepostpartum symptoms.

Unfortunately, many men laugh off the idea of paternalpostpartum depression. And even if they accept its the real deal, they might notadmit its affecting them.

But theres nothingshameful about postpartum depression, Dr. Bea stresses. Fatherhood is a hugenew job, with long hours and no pay, and society doesnt do a good enough jobsupporting men in this role.

To maintain a positive mood when youre in the thick of newfatherhood, Dr. Bea recommends focusing on the self-care basics:

Adjusting to a new baby takes time. Its normal for yourmood to be a little rocky in the process. But if your symptoms last more than twoto three weeks, consider help from a counselor or psychotherapist.

Asking for helpdoesnt mean youre helpless, Dr. Bea points out. It means youre doing whatyou need to do so you can be the best partner and best dad you can be.

View post:
Yes, Postpartum Depression in Men Is Very Real - Health Essentials from Cleveland Clinic

Struggling to shift the pounds and keep them off? Well, according to one of Harley Streets leading nutritional therapists, it could be down to your own hormones.

Stephanie Webster, who works with at the Urban Health Method Clinic in London, believes optimising our hormones may be the key to getting rid of unwanted weight gain. She thinks understanding our body and whats going on inside them could help women find the most effective solution for their weight loss struggles and hormonal weight gain.

The Urban Health Method Clinic uses the DUTCH Plus test, which is a comprehensive test of all 35 different horomones, to identify and highlight hormone imbalances in our bodies. Particular attention is paid to the stress hormone cortisol, which has been linked to hormonal weight gain. Hormones are about much more than just sex; they play a role in practically every human function, and actually influence everything from mental agility and body composition to how quickly we age, explains Stephanie. Even minor hormone imbalances, which occur naturally as we get older, can have a huge effect on our overall health and well-being. But many people, particularly women, are suffering in silence.

Stephanie explains that if you understand your bodys personal needs, you can then speak to your GP about supplementing your diet with the right bioidentical hormones. Bioidentical hormones are man-made hormones that are very similar to the hormones produced by the human body. Common bioidentical hormones that are matched are oestrogen, progesterone and testosterone. These are used for treatment in both men and women whose own hormones are low or out of balance.

Hormones are chemicals produced by different glands and tissues in the body and are responsible for regulating several processes in the body, such as appetite and metabolism, sleep cycles, heart rate, stress levels and body temperature. Women may experience imbalances (too much or too little of a certain hormone) in insulin, cortisol, thyroxin, androgens, oestrogen and progesterone, and this can impact your body.

Excess insulin,in particular, can cause weight gain and inflammation, by storing too much fat, while too much cortisol can shut down digestion and slow down your metabolism. If left it can cause high blood sugar, increased belly fat, high blood pressure and high cholesterol.

If you have a hormonal imbalance then you should speak to your GP about bioidentical hormones. But Stephanie advocates that you think about wider lifestyle changes. She reveals that she has identified that clients who also focus on improving their diet and minimising their stress levels can naturally work to optimise their hormones, resulting in accelerated fat loss. She recommends a diet free of processed and junk foods and high in protein.

Ultimately, Stephanie believes in prevention over cure, which is why they offer a wide range of diagnostic services, including health tests, DNA tests and body composition tests to help you care for your body and minimise disease risk, through simple, yet effective lifestyle choices, such as eating a healthy diet, boosting activity levels and understanding what your body needs to perform optimally.

If you believe that you might have a hormonal imbalance we recommend that you speak to your GP.

Read this article:
Are your hormones the reason youre not losing weight? - woman&home

Fatal blood clots, suicidal behavior, lowered IQs, brittle bones and sterility are just a few of the potential side effects of puberty blockers that the transgender industry doesnt want talked about.

Thousands of children attending affirmative gender health clinics globally, including in the United States and the United Kingdom, are being given powerful puberty-blocking drugs with a litany of serious side effects including death according to Food and Drug Administration data.

And the National Health Service (NHS) in England is currently investigating issues surrounding use of the drugs since it registered a 4,500% increase last fall in the number of youths seeking treatments to alter their biological sex in the previous nine years.

The drugs, sometimes referred to as chemical castrators because they are used to treat sex offenders, are increasingly used as a first-line treatment for gender-confused children as young as 10 years old when they are referred to counseling.

Frequently on their first consultation, children and teens are implanted with hormone-blocker-releasing rods or taught to self-inject the drugs to pause their adolescence and prevent developmental changes, like growth of breasts and facial hair while they decide on which sex they would like to identify.

The practice recently gained the endorsement of the Endocrine Society and the American Academy of Pediatrics, but the Food and Drug Administration has not licensed the drugs for transgender medicine due to lack of supportive evidence. They are approved for treating prostate cancer and uterine pain in adults. The agency has recorded more than 41,000 adverse events reported with their use between 2013 and June 30, 2019.

More than 26,000 of the events associated with the two hormone blockers, Leuprolide acetate and triptorelin (which includes Lupron and similar drugs used by clinics), were classified by the federal agency as serious, including 6,370 deaths. The drugs, which dramatically lower testosterone and estrogen levels in the body, are linked to life-threatening blood clots and other complaints, include brittle bones and joint pain.

Inducing Disease

The recent increase in the number of gender dysphoric youths seeking drug treatments is particularly alarming to experts who see the drugs effects as too risky to prescribe in their current form if at all.

Michael Laidlaw, an endocrinologist from Rocklin, California, testified before the British House of Lords on the issue of transgender health care in May. Laidlaw told the Register, These drugs actually induce a known disease in previously hormonally healthy children.

Puberty blockers, he explained, interfere with normal signals between the brain and the sex organs, thereby creating a disease state called hypogonadotropic hypogonadism in youths. Its a serious condition that endocrinologists would normally diagnose and treat because it interferes with development, but in [gender dysphoria] cases theyre inducing this disease state, Laidlaw said.

Because the drugs are relatively new, their long-term effects have yet to be fully determined, but one 2018 study of long-term risks of puberty blockers from researchers at Boston Childrens Hospital found that while side effects of the drugs are advertised to resolve three-six months after stopping treatment, in actuality, the majority of subjects reported long-term side effects while almost one-third reported irreversible side effects that persisted for years after discontinuing treatment.

In addition to experts, those who have experienced the drugs effects are also raising the alarm.

On social-media platforms, women describe crippling long-term side effects after taking the drugs as children. One woman on a Facebook page called BAN Lupron said she was given Lupron for years as a young child to stop premature puberty, and now, as a 24-year-old mother of two, I have [a] herniated disc in my lower lumbar, S-I Joint dysfunction, [a] shredded meniscus in my right knee shoulder pain tendonitis in my left foot, extreme tooth decay and minimal teeth left, TMJ [jaw pain].

A 25-year-old said on the page that she suffers from osteoporosis and a cracked spine, while a 26-year-old indicated the need for a total hip replacement.

Youths who take puberty blockers complain of similar side effects and of menopausal symptoms, including hot flashes, insomnia, fatigue, rapid weight gain and depleted bone density.

I stubbed my toe; it broke. I fell over; my wrist broke. Same with my elbow, an anonymous teen, who was prescribed the drugs by the Tavistock NHS gender center, told the Times newspaper of London.

They promise you that your breasts will disappear, that your voice will be deeper, that I would look and sound more like a boy. For me, that was the best thing that could have happened, the teen said about her attitude at the time, but she came to call taking the drugs the worst decision Ive ever made.

Evolving Guidelines

These and similar complaints have come to the attention of some members of the medical community, who urge some kind of government oversight.

Yes, there can be poor or improper treatments by some; thus, governments as well as medical organizations should investigate reports of patient/family complaints in this regard, Michigan State University pediatrician Donald Greydanus told the Register. Greydanus is one of eight authors of a paper, published in the August issue of the journal Disease-a-Month, overviewing care of teens who identify as transgender.

Greydanus is not necessarily opposed to the use of castration drugs, but he acknowledges that prudence must still play a role in how they are administered especially since the drugs have a sketchy safety record.

Adolescents with gender dysphoria should not be started on puberty blockers until at least early adolescence, he said. Sex-affirming hormone therapy using high levels of hormones of the opposite sex may start soon after, and surgery by age 18, generally, but he said, These guidelines continue to evolve and to be debated!

Greydanus added that proper informed consent should let all parties know the drugs risks before they are given.

All drugs have side effects, he told the Register, and some can be worse in some patients versus others.

However, Laidlaw called the hormone-blocking drugs untested and unsafe for adolescent children. He referred to them as development blockers because their results are systemic and block normal brain development and a host of other body functions as well as sexual maturation.

Development is so stunted, he said. If you take these long-term, you wind up with an adult with child-like sex organs. If they are taken at a very early stage, they wont develop sperm. Permanent infertility is a possible outcome for those who use the drugs, he said.

Puberty is a time of tremendous growth and not just in the gonads, he said, noting that bone formation is also taking place at this time. They are lengthening as well as strengthening.

The effects of the drugs on bone density are well-documented, Laidlaw said. By the end of two years the bone density of the girls [taking puberty blockers] is down in the lowest 3%.

Mental-Health Concerns

According to guidelines from the World Professional Association for Transgender Health, children must be screened for underlying mental issues. Yet a Freedom of Information request filed by Oxford sociologist Michael Biggs revealed that nearly one-third of the children treated at one clinic in Britain had been diagnosed with autism spectrum disorder.

Besides putting patients with pre-existing mental conditions at risk, the drugs also seem to be having a deleterious effect on young patients developing mental capacities, studies have shown.

Puberty is also a time of tremendous brain changes, when gray matter becomes denser which may explain why puberty blockers have been found to lower IQ.

One 2016 study found that girls treated with puberty blockers had an eight-point lower IQ score than controls who did not receive the treatment. This was similar to the seven-point IQ drop from 100 to 93 reported among 25 girls who took puberty blockers for two years for early puberty and a nine-point IQ drop in a study of a 12-year-old boy 28 months after taking the blockers.

Proponents of the drugs claim the effects are reversible, but we dont know what will happen in all the cases, Laidlaw said.

But the mental damage may be even more serious than a drop in IQ for patients.

Concerns about the impact of puberty-blocking drugs on the mental health of youths were raised in England when Biggs uncovered the unpublished results of a study by the Tavistock and Portman NHS Trusts Gender Identity Development Service (GIDS).

Although the results for using puberty blockers had been reported to the public as positive, Biggs found that for all but one yardstick (that of parents perspective) the outcomes were negative and that a significant increase was found in the number of drug-treated youths who agreed with the statement: I deliberately try to hurt or kill self.

Transgender Censorship

But even scientific evidence pointing to the risks of castration drugs doesnt seem to matter to the cultural gatekeepers who wish to see transgenderism normalized in society.

Demand for the drugs as puberty blockers has skyrocketed with government-sponsored and cultural transgender programming, including television shows like I Am Jazz, an American reality TV following Florida teen Jazz Jennings, who was born male but took hormones and was surgically castrated to appear female. And the market for the drug has a potential to expand further, as gender science is extending to transgender preschool children.

With such positive reinforcement of transgenderism in culture, criticism of treatment for gender dysphoria is increasingly banned as harmful and transphobic. The same tendency toward censorship also surfaced recently in state legislation. Last month, North Carolina became the 18th state to ban the use of taxpayer dollars for any conversion therapy practices that seek to help transgender children overcome their confusion without drugs and surgery.

Experts in the field are also not immune to such censorship. Laidlaw told the Register that as an endocrinologist, he tweeted on July 21 about the dangers of puberty blockers but his tweet was deleted by Twitter last month, and he has been unable to post on the platform since.

Likewise, when Biggs revealed the unpublished GIDS report to the British press, the Oxford professors Twitter account was reportedly suspended for transphobic statements.

Catholic Teaching

Aside from the medical risks involved with castration drugs, the principle driving their promotion flies in the face of Catholic teaching on human sexuality.

Pope Francis addressed the issue of transgenderism in his 2015 encyclical Laudato Si (Care for Our Common Home), citing the words of his predecessor, Benedict XVI, that man too has a nature that he must respect and that he cannot manipulate at will.

Man, Benedict said inhis September 2011 address to the German Parliament, does not create himself. He is intellect and will, but he is also nature, and his will is rightly ordered if he respects his nature, listens to it and accepts himself for who he is, as one who did not create himself.

[V]aluing ones own body in its femininity or masculinity is necessary if I am going to be able to recognize myself in an encounter with someone who is different, Pope Francis added. In this way we can joyfully accept the specific gifts of another man or woman, the work of God the Creator, and find mutual enrichment.

Celeste McGovern writes from Nova Scotia, Canada.

See the original post:
FDA: Thousands of Deaths Associated With Drugs Given to 'Trans' Children - National Catholic Register

TheGender Identity Development Service (GIDS), run by the Tavistock and Portman National Health Service (NHS) Trust in the UK is offering appointments, diagnosis, and even medication for children who are "transitioning" because they suffer from gender dysphoria. The children in question can be as young as three years old.

The Daily Mail reported, "last year 2,590 children were referred to the clinic, a rise of more than 400 per cent since 2013, leading to a two-year waiting list." This waiting list is one of the reasons the clinic will now offer online treatment. "Ten of the children were aged three or four and dozens more were of primary-school age. The treatment includes giving the children hormone-blocking drugs."

Puberty-blocking drugs are highly controversial and can lead to infertility and sterilization. A review of the scientific evidence for this procedure was done byPaul W. Hruz,Lawrence S. Mayer, andPaul R. McHugh and found that "the evidence for the safety and efficacy of puberty suppression is thin, based more on the subjective judgments of clinicians than on rigorous empirical evidence. It is, in this sense, still experimental yet it is an experiment being conducted in an uncontrolled and unsystematic manner. In their detailed and meticulously-researched article, they raise troubling questions in regards to side-effects and consequences of using puberty-blocking drugs.

Even as experts are sounding alarm bells about the safety of such drugs, the doctors of NHS are increasing the number of children they prescribe them to exponentially by adding "telemedical" appointments to their process.

A spokesman for the Tavistock and Portman Trust told The Daily Mail they are "using digital technologies to increase efficiency and to enhance patient experience where appropriate is an area of development across the NHS." They went on to say, "The Trust is working to minimise waiting times and make clinical support easier to access, including eliminating travel time for young people and their families, which will also allow us to offer appointments earlier and later in the day."

The clinic is offering this "sex change by Skype" in the middle of rising controversy from psychologists and other professionals who say these methods are rushing children towards irreversible consequences. Some experts are calling this method child abuse. PJ Media's Tyler O'Neil recently spoke to Dr. Michael Laidlaw, an edocrinologist, who says these drugs are giving children a disease.

"I call it a development blocker its actually causing a disease,"Dr. Michael Laidlaw, anindependent private practiceendocrinologist in Rocklin, Calif. who consults with Sutter Roseville Medical Center, told PJ Media. The disease in question is hypogonadotropic hypogonadism. It occurs when the brain fails to send the right signal to the gonads to make the hormones necessary for development.

The rush forward to add more and more children to an untested experiment that can cause lifelong injury is a head-scratching fact of modern medicine. The BBC investigation video below shows that dangerous practices in this area of medicine are continuing without pause.One can only hope that the victims who will be injured by these experiments will file lawsuits to finally put an end to it.

Megan Fox is the author of Believe Evidence; The Death of Due Process from Salome to #MeToo. Follow on Twitter @MeganFoxWriter

Read the original:
UK Gender Clinic Will Push Kids to Puberty Suppression Online - PJ Media

For two weeks every month Rachel* would be engulfed in a depression so deep she felt like she was walking through treacle. As a gifted athlete and high achiever academically, it was entirely out of character.

Half the month I was extroverted, firing on all cylinders, Rachel says. Then I would hit ovulation. And at that time I became dysfunctional, shy and withdrawn. Its like I woke up one day and became a completely different person. And from then until I started menstruating I became utterly dysfunctional. Then I would get my period and I would be fine. And this happened again and again and again.

She says these symptoms which doctors have now attributed to premenstrual dysphoric disorder, or PMDD have affected intimate relationships and friendships over the years because she would withdraw socially if she felt the fog of depression closing in: I couldnt stand myself so how could anyone else?

PMDD affects between 3% and 8% of women of reproductive age. Its caused by fluctuations in hormone levels which affect brain chemistry and result in severe mood disturbances, says Prof Jayashri Kulkarni, a psychiatrist and director of the Monash Alfred psychiatry research centre at Monash University in Melbourne.

Unlike PMS, which hits two to four days out from menstruation with various physical and emotional symptoms, the onset of PMDD is one to two weeks before a woman gets her period, known as the luteal phase. It results in a sudden and significant depression and lifts just as abruptly when the womans period begins.

This is a condition where there are significant depression symptoms, and that can include suicidal thoughts and suicide attempts, some of which are, tragically, realised, says Kulkarni, who has been working in and researching the area of womens mental health for almost 30 years.

Some of the key features of PMDD are when a woman says, Its like someone flicked a switch. Im OK, then suddenly, bang, there is a major depression. I cant get out of bed, I cant think. I get tearful, I get irritable, I get angry, I cant process cognitively very well.

Kulkarni says PMDD symptoms, including anxiety, rage and hostility all symptoms of depression although often not recognised as such can wreak havoc on relationships. All sorts of things can go astray, including work performances and relationships with colleagues, she says.

Kulkarni has seen adolescents as young as 12 affected, all the way through to women nearing menopause, when the condition typically worsens.

Although women have been battling this condition for generations, PMDD has been recognised as a clinical mental health condition for only six years. In 2013 it was included as a depressive disorder in the Diagnostic and Statistical Manual of Mood Disorders, published by the American Psychiatric Association.

There are some women who are more sensitive to their hormone fluctuations than others

Significantly, a gene related to PMDD was found by researchers from the US National Institutes of Health and published in the journal Molecular Psychiatry in 2017. It points to a biological predisposition for those women who are extra sensitive to the normal hormonal fluctuations in their cycles. At the time the gene discovery was published, an NIH researcher, Dr David Goldman, said: This is a big moment for womens health because it establishes that women with PMDD have an intrinsic difference in their molecular apparatus for response to sex hormones not just emotional behaviours they should be able to voluntarily control.

Its a pivotal time for womens wellbeing in Australia. Its a time when womens health issues, like endometriosis, are finally being talked about and taken seriously evidenced by the $10m federal government funding boost for endometriosis research and awareness announced earlier this year by the health minister, Greg Hunt.

Kulkarni is at pains to emphasise that PMDD is not just below the belt but a condition with its epicentre in the brain.

She says all the hormones involved in a womans cycle progesterone, oestrogen and testosterone are potent brain chemicals.

Progesterone, and in particular allopregnanolone (a hormone produced when progesterone is broken down in the brain), is thought to be a major cause of PMDD, she says. But oestrogen protects the brain in many ways, and imbalances in progesterone and oestrogen in the brain can lead to the depression symptoms seen in women with PMDD.

These are all very potent hormones. And there are some women who are more sensitive to their hormone fluctuations than others.

Rachel is one of those women. Her experience can be traced back to adolescence, but she was officially diagnosed only six years ago, in her early 30s, after years searching for an answer. A red flag for Rachel, as well as her depressive symptoms, was when her inner dialogue would suddenly nosedive into negative self-talk. There would suddenly be a shift an almost bullying way of talking to myself that wasnt characteristic of me, she says.

A PMDD diagnosis requires women to experience at least five symptoms in the final week before her period, which improve when menstruation starts and are minimal or absent in the remaining weeks of her cycle. These include mood swings, irritability, anger, anxiety, tension, fatigue, difficulty concentrating, social withdrawal and as Rachel experienced self-deprecating thoughts. There can be physical symptoms too, such as breast tenderness or swelling, joint or muscle pain, and a sensation of bloating or weight gain. Often women are asked to keep a diary to note the symptoms for several cycles before a diagnosis is reached.

Treatment can vary from practitioner to practitioner and from patient to patient the same approach does not necessarily work for everyone. Kulkarni works closely with an endocrinologist and favours a multipronged approach involving hormone modulation experimenting with doses of progesterone and oestrogen (including the contraceptive pill and oestrogen patches) underpinned by psychological support. Low doses of antidepressant medication are added if needed but are not the first line of treatment. In the worst-case scenario, when women are not responding to any other treatments, inducing menopause with medication is an option.

The thing is, womens mental health is not a national priority and it should be

We have in the past had to resort to chemical menopause, at the very severe end, where somebody is profoundly depressed and their life is at risk, she says. Thats an extreme approach and very few people need it. Its essentially shutting off those hormonal fluctuations. And weve had some great successes in women who have tried everything else and nothing has worked.

Kulkarni says hysterectomies are not advocated by the clinic unless there is a very clear physical health reason beyond PMDD, such as additional complications with fibroids or severe endometriosis.

For Rachel the combination of psychological support, hormonal and anti-depressant treatment has allowed her to manage her condition, although it has taken time.

The big thing I have noticed in the past six months in particular is that the fog has lifted, she says. There isnt this cognitive fog, this sense of walking through treacle, which was the fatigue I had a lot of the time.

She says she found it hard to confide in anyone about her condition, including female friends. In the past she would reach out if she was struggling but with PMDD, she feels there is still a stigma and a lack of language around how to talk to others about a womens health condition.

Even between other women, just saying, My hormones at the moment mean that I dont feel like myself. How do we talk about that?

The thing that has really hit me with all this, is that mood isnt just depression and anxiety. It sits so much within your hormones and broader health. That our experience of those things, as women, are so interrelated with our hormones and we just dont talk about it. Its because its womens health.

Kulkarni agrees and says awareness needs to be raised nationally around womens mental health: The thing is, womens mental health is not a national priority and it should be.

* Name has been changed

Excerpt from:
'Like someone flicked a switch': the premenstrual disorder that upturns women's lives - The Guardian

Doctors have long known that playing high-intensity sports can trigger serious heart rhythm problems in people with certain underlying heart conditions. Now, a new report suggests that playing electronic games particularly war games may be a trigger as well.

The report, from researchers in Australia, describes three unrelated cases of children who fainted while playing electronic war games. All of these children had underlying conditions that affect the heart's electrical system and can be life-threatening. But in two of the cases, the child's heart problem wasn't discovered until after they fainted while gaming.

The intense, emotionally-involved play of the games may result in the release of stress hormones that could be a trigger for heart rhythm problems in susceptible people, experts said.

Related: Top 10 Amazing Facts About Your Heart

In the first case, a 10-year-old boy suddenly lost consciousness at home after winning the war game he was playing, according to the report, published Sept. 19 in the New England Journal of Medicine. He soon regained consciousness and seemed alright. But later, the boy experienced a cardiac arrest at school due to a life-threatening condition known as ventricular fibrillation, in which the heart quivers instead of beating properly. He was diagnosed with a rare condition called catecholaminergic polymorphic ventricular tachycardia (CPVT), a heart rhythm disorder that results from a genetic mutation, according to the National Institutes of Health.

The second case involved a 15-year-old boy who had previously undergone heart surgery to repair a hole in his heart that he was born with. The boy started to faint right as he was about to win the war game he was playing. He was diagnosed with ventricular tachycardia, a heart rhythm disorder in which the heart beats faster than normal, and the lower heart chambers are out of sync with the upper chambers, according to the Mayo Clinic.

The boy received a device known as an implantable cardioverter-defibrillator (ICD), which detects and stops abnormal heartbeats. About two months later, the boy experienced another episode of ventricular tachycardia, again while he was about to win his game. But the ICD successfully restored his heart rhythm.

In the third case, an 11-year-old boy collapsed after having heart palpitations while "animatedly playing an electronic war game with a friend," the report said. He regained consciousness and was diagnosed with long-QT syndrome, a heart rhythm condition that can cause irregular heartbeats. The condition can be genetic, and the boy later had two family members diagnosed with long-QT syndrome.

Dr. Ronald Kanter, a cardiologist and director of electrophysiology at Nicklaus Children's Hospital in Miami, who wasn't involved in the report, said he hadn't heard of electronic games triggering heart rhythm problems prior to this study. However, Kanter said he wasn't surprised that it happened.

"Anything that causes a sudden surge of the body's stress hormone adrenaline can put vulnerable patients at risk of going into a dangerous heart rhythm," Kanter told Live Science.

Both long-QT syndrome and CPVT are notorious for causing heart rhythm problems triggered by emotional stress, in addition to physical stress, he added.

"These electronic games are emotionally stressful, that's part of the thrill of them," Kanter said. "It shouldn't surprise anybody really."

Heart conditions that can lead to dangerous rhythm problems are not all that rare, Kanter said.

However, "the likelihood of a youngster who participates in electronic gaming having an event is probably very very uncommon," given that so many young people do this kind of gaming, he said.

It's unclear at this time whether children with heart rhythm problems should avoid playing electronic games. The new report appears to be one of the first to link heart rhythm problems with electronic gaming. "We don't know what kind of risk their really is," Kanter said.

What's more, children diagnosed with heart rhythm problems were once told they couldn't play high-intensity sports. But now, even those recommendations are changing, Kanter said.

For example, in some cases, people with long-QT syndrome may be able to participate in competitive sports, after carefully reviewing the risks and benefits with a doctor, the Mayo Clinic says.

Kanter said there will likely be a lot of discussion and research going forward on whether children with heart rhythm problems should avoid electronic games. With this one report, "we're only at the beginning of that experience," he said.

Originally published on Live Science.

Visit link:
Gaming May Trigger Heart Rhythm Problems in Susceptible Kids, Report Says - Livescience.com

For mild cases of hypothyroidism, not all patients need treatment. File photo/TNS

Dear Mayo Clinic: I recently was diagnosed with mild hypothyroidism that isnt causing symptoms. My doctor says I dont need treatment now, but she wants me to come back for regular checkups. Does hypothyroidism usually get worse over time? If it does, how is it treated?

A: For mild cases of hypothyroidism, not all patients need treatment. Occasionally, the condition may resolve without treatment. Follow-up appointments are important to monitor hypothyroidism over time, however. If hypothyroidism doesnt go away on its own within several months, then treatment is necessary. If left untreated, this condition eventually may lead to serious health problems.

The thyroid gland is a small butterfly-shaped gland in the front of the neck that makes the hormones triiodothyronine, or T3, and thyroxine, or T4. Those hormones affect all aspects of your metabolism. They maintain the rate at which your body uses fats and carbohydrates, help control your body temperature, influence your heart rate, and help regulate the production of proteins. The amount of thyroid hormones your body makes is regulated by another hormone called thyroid stimulating hormone, or TSH, thats produced by the pituitary gland.

Hypothyroidism develops when the thyroid doesnt make enough hormones. As a result, your metabolism slows down. As thyroid activity slows, the level of T4 in your body decreases, and the level of TSH increases to encourage the thyroid gland to raise T4 production.

Some mild cases of hypothyroidism, called subclinical hypothyroidism, are associated with an elevated TSH while the T4 level stays within the normal range. At that point, the condition may not produce any noticeable symptoms. But if the decrease inT3 and T4 continues (referred to as overt hypothyroidism), it can affect many bodily functions.

Common early symptoms of hypothyroidism include unexplained weight gain, fatigue and low energy. It also may cause dry skin, constipation, sensitivity to cold, a puffy face, muscle weakness, hoarseness, and joint pain or stiffness.

See original here:
Mild hypothyroidism may not need treatment - Gulf Today